CASE REPORT article
Front. Med.
Sec. Dermatology
Volume 12 - 2025 | doi: 10.3389/fmed.2025.1637045
This article is part of the Research TopicExploring Innovative Therapies for Rare Inflammatory Skin DiseasesView all 10 articles
Case Report: Successful treatment of a novel variant of CARD14-mutated juvenile Pityriasis rubra pilaris with Ixekizumab
Provisionally accepted
- 1Department of Dermatology, Eberhard Karls University, Tuebingen, Germany
- 2Universitatsklinikum Freiburg, Freiburg, Germany
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Pityriasis rubra pilaris (PRP) is a rare inflammatory papulosquamous skin disease without any approved treatment options. Variants in the CARD14 (caspase recruitment domain family member 14) gene have been identified to play a role in the pathophysiology of atypical juvenile PRP by activating the IL-23/IL-17A cytokine axis, highlighting this pathway as a potential target of therapy. Here, we present a case of successful treatment with Ixekizumab, a humanized monoclonal anti-IL-17A antibody, in an atypical juvenile PRP (type V) patient with a novel variant of CARD14 mutation.
Keywords: Pityriasis Rubra Pilaris, case report, Ixekizumab, CARD14, Pediatric dermatology
Received: 28 May 2025; Accepted: 03 Jul 2025.
Copyright: © 2025 Millak, Hahn, Fischer and Volc. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Matthias Hahn, Department of Dermatology, Eberhard Karls University, Tuebingen, Germany
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.